Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction

Anne-Laure Leblond, John O&rsquo;Sullivan, Noel Caplice1Centre for Research in Vascular Biology (CRVB), Biosciences Institute, University College Cork, Cork, IrelandAbstract: Despite advances in the management of myocardial infarction, congestive heart failure following myocardial infarction...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne-Laure Leblond, John O&rsquo;Sullivan, Noel Caplice
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/f06cc6aac9c4480c986f918d30eff0fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f06cc6aac9c4480c986f918d30eff0fe
record_format	dspace
spelling	oai:doaj.org-article:f06cc6aac9c4480c986f918d30eff0fe2021-12-02T01:37:19ZBone marrow mononuclear stem cells: potential in the treatment of myocardial infarction1178-6957https://doaj.org/article/f06cc6aac9c4480c986f918d30eff0fe2009-12-01T00:00:00Zhttp://www.dovepress.com/bone-marrow-mononuclear-stem-cells-potential-in-the-treatment-of-myoca-a3799https://doaj.org/toc/1178-6957Anne-Laure Leblond, John O&rsquo;Sullivan, Noel Caplice1Centre for Research in Vascular Biology (CRVB), Biosciences Institute, University College Cork, Cork, IrelandAbstract: Despite advances in the management of myocardial infarction, congestive heart failure following myocardial infarction continues to be a major worldwide medical problem. Mononuclear cells from bone marrow are currently being studied as potential candidates for cellbased therapy to repair and regenerate damaged myocardium, with mixed results. The success of this strategy requires structural repair through both cardiomyogenesis and angiogenesis but also functional repair. However, pre-clinical and clinical studies with the intracoronary administration of cells indicate limited cardiomyogenesis and cell survival, controversial functional benefit and suggest paracrine effects mediated by the administered cells. Further investigations for optimizing therapeutic benefit focus on the requirement for stable cell engraftment and the involvement of cytokines in this process. This includes a large and varied range of strategies including cell or heart pre-treatment, tissue engineering and protein therapy. Although cellbased therapy holds promise in the future treatment of myocardial infarction, its current use is significantly hampered by biological and technological challenges.Keywords: bone marrow mononuclear cells, myocardial infarction, cardiac cell therapy Anne-Laure LeblondJohn O&rsquo;SullivanNoel CapliceDove Medical PressarticleCytologyQH573-671ENStem Cells and Cloning: Advances and Applications, Vol 2009, Iss default, Pp 11-19 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Anne-Laure Leblond John O&rsquo;Sullivan Noel Caplice Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
description	Anne-Laure Leblond, John O&rsquo;Sullivan, Noel Caplice1Centre for Research in Vascular Biology (CRVB), Biosciences Institute, University College Cork, Cork, IrelandAbstract: Despite advances in the management of myocardial infarction, congestive heart failure following myocardial infarction continues to be a major worldwide medical problem. Mononuclear cells from bone marrow are currently being studied as potential candidates for cellbased therapy to repair and regenerate damaged myocardium, with mixed results. The success of this strategy requires structural repair through both cardiomyogenesis and angiogenesis but also functional repair. However, pre-clinical and clinical studies with the intracoronary administration of cells indicate limited cardiomyogenesis and cell survival, controversial functional benefit and suggest paracrine effects mediated by the administered cells. Further investigations for optimizing therapeutic benefit focus on the requirement for stable cell engraftment and the involvement of cytokines in this process. This includes a large and varied range of strategies including cell or heart pre-treatment, tissue engineering and protein therapy. Although cellbased therapy holds promise in the future treatment of myocardial infarction, its current use is significantly hampered by biological and technological challenges.Keywords: bone marrow mononuclear cells, myocardial infarction, cardiac cell therapy
format	article
author	Anne-Laure Leblond John O&rsquo;Sullivan Noel Caplice
author_facet	Anne-Laure Leblond John O&rsquo;Sullivan Noel Caplice
author_sort	Anne-Laure Leblond
title	Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
title_short	Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
title_full	Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
title_fullStr	Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
title_full_unstemmed	Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
title_sort	bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/f06cc6aac9c4480c986f918d30eff0fe
work_keys_str_mv	AT annelaureleblond bonemarrowmononuclearstemcellspotentialinthetreatmentofmyocardialinfarction AT johnoamprsquosullivan bonemarrowmononuclearstemcellspotentialinthetreatmentofmyocardialinfarction AT noelcaplice bonemarrowmononuclearstemcellspotentialinthetreatmentofmyocardialinfarction
_version_	1718402990879014912

Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction

Ejemplares similares